Jun Chen

Jun Chen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2022 in Gene
Verified
Journal Article
Closed access
ZRZe Rong
Ze Rong
KZKaifeng Zheng
Kaifeng Zheng
JCJun Chen
Jun Chen
XJxiaofeng jin
xiaofeng jin

14 June 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YZYiting Zhao
Yiting Zhao
MLMan Lin
Man Lin
FZfengguang zhai
fengguang zhai
JCJun Chen
Jun Chen
XJxiaofeng jin
xiaofeng jin
Parkinson’s disease (PD) is a prevalent neurodegenerative disorder among the elderly population. The pathogenesis of PD encompasses genetic alterations, environmental factors, and age-related neurodegenerative processes. Numerous studies have demonstrated that aberrant functioning of the ubiquitin–proteasome system (UPS) plays a crucial role in the initiation and progression of PD. Notably, E3 ubiquitin ligases serve as pivotal components determining substrate specificity within UPS and are intimately associated with the regulation of various proteins implicated in PD pathology. This review comprehensively summarizes the mechanisms by which E3 ubiquitin ligases and deubiquitinating enzymes modulate PD-associated proteins and signaling pathways, while exploring the intricate relationship between UPS dysfunctions and PD etiology. Furthermore, this article discusses recent research advancements regarding inhibitors targeting PD-related E3 ubiquitin ligases.

20 December 2022 in Gene
Verified
Journal Article
Closed access
YZYiting Zhao
Yiting Zhao
WYWeili Yang
Weili Yang
KZKaifeng Zheng
Kaifeng Zheng
JCJun Chen
Jun Chen
XJxiaofeng jin
xiaofeng jin

11 July 2022 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
YZYiting Zhao
Yiting Zhao
JLJinyun Li
Jinyun Li
JCJun Chen
Jun Chen
MYMeng Ye
Meng Ye
XJxiaofeng jin
xiaofeng jin

28 July 2020 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
HLHui Li
Hui Li
XZXin Zhou
Xin Zhou
DZDing Zhang
Ding Zhang
GWGuoqiang Wang
Guoqiang Wang
XCXiaochun Cheng
Xiaochun Cheng
JCJun Chen
Jun Chen
Background: Immune checkpoint inhibitors (ICIs) have shown clinical benefit in many advanced tumors, however, pseudo-progression is a noted phenomenon of ICIs characterized by radiologic enlargement of the tumor burden, followed by regression. How to differentiate pseudo-progression from progression remains a critical clinical issue. Recent studies have demonstrated the association between immune-related adverse events (irAEs) and efficacy of ICIs. Here we demonstrated an ovarian cancer patient treated with nivolumab in whom the early-onset irAE was identified to differentiate pseudo-progression from progression. Case presentation: Here we present the case of a 47-years-old woman with histopathologically confirmed diagnosis of metastatic ovarian cystadenocarcinoma. Immunohistochemical examination showed 10% of tumor cells to express the programmed cell death receptor ligand 1 (PD-L1) and a 381-gene panel sequencing in a College of American Pathologists (CAP) certificated lab revealed a moderate mutational tumor burden with 5.7 Mutants/Mb. The patient received nivolumab 100 mg every 2 weeks as a fourth line treatment. Within the first 2 months, the tumor volume increased by 23.6%. However, the patient experienced an elevation of Alanine aminotransferase (ALT) and Aspartate aminotransmerase (AST), which was diagnosed as the immune-related hepatitis. Thus, the treatment continued and afterwards, the patient reached a partial response (PR) to nivolumab and the progression-free survival was 9 months. Conclusion: To our knowledge, this is the first case describing early-onset immune-related adverse events to identify pseudo-progression in a patient with ovarian cancer treated with nivolumab, and PD-L1 expression level may be a predictive biomarker in the immunotherapy of ovarian cancer.

23 March 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
ZRZe Rong
Ze Rong
KZKaifeng Zheng
Kaifeng Zheng
JCJun Chen
Jun Chen
XJxiaofeng jin
xiaofeng jin
Ubiquitination, a highly adaptable post-translational modification, plays a pivotal role in maintaining cellular protein homeostasis, encompassing cancer chemoresistance-associated proteins. Recent findings have indicated a potential correlation between perturbations in the ubiquitination process and the emergence of drug resistance in CRC cancer. Consequently, numerous studies have spurred the advancement of compounds specifically designed to target ubiquitinates, offering promising prospects for cancer therapy. In this review, we highlight the role of ubiquitination enzymes associated with chemoresistance to chemotherapy via the Wnt/β-catenin signaling pathway, epithelial–mesenchymal transition (EMT), and cell cycle perturbation. In addition, we summarize the application and role of small compounds that target ubiquitination enzymes for CRC treatment, along with the significance of targeting ubiquitination enzymes as potential cancer therapies.